Drug discovery is getting more expensive and slower. Eroom's law states that the cost of developing new drugs has doubled every nine years since the 1950s. Today, it takes 10 to 15 years and billions of dollars to bring a molecule to market. Artificial intelligence promises to speed things up — but there's a catch: data.
According to a July 2026 MIT Technology Review analysis, the real bottleneck is not the algorithm but the quality and availability of clinical, genomic and lab data. Big pharma and big tech (Google DeepMind, Nvidia, Microsoft) are building closed ecosystems, training models on proprietary data. Europe, with its public healthcare data heritage and GDPR regulations, risks being left out of the game.
Why it matters for small businesses and Italy
This isn't just a multinational problem. Italian pharma and biotech SMEs — and there are excellent ones from Lombardy to the South — will depend on models trained on US or Chinese data. Translation: licences, royalties, strategic dependency. If the model doesn't know the genetic variants of the Italian population or side effects on Mediterranean patients, results will be less reliable for us. And the cost of adapting it becomes another entry barrier.
Sponsored Protocol
We at Meteora Web have been working with inventory and customer data for years. We know a model is only as good as the data it's built on. If Europe doesn't create a strategy to aggregate and make its clinical data usable — respecting privacy but without blocking research — it will end up buying solutions from others, paying twice: once for development, once for access.
Our position is clear: open data yes but with European intelligence
We are not against AI. We are against blind delegation. Europe already lost the consumer cloud, search engines, social media. The pharmaceutical sector is too vital to be given away. We need public investment in interoperable data infrastructure with European standards. We need Italian startups working on models trained on local data. And we need regulation that is not only defensive (GDPR) but also proactive (incentives for data sharing in research).
Sponsored Protocol
Technology is just a tool. Whoever owns the data owns the future. And in that future, Italy cannot afford to be just a market opportunity.
What to do right now
If you are an entrepreneur or researcher in Italian biotech, ask your political representatives for funding for open data platforms governed by Europe. If you develop software, think about models that can be trained on Italian health data while complying with GDPR, perhaps through federated learning. Don't wait for Big Pharma to set the rules. The time to act is now, before European clinical data becomes an appendix of American ones.
